



Guest Speakers for Sophiris Investor Call to Review Topsisyn Clinical Data



Marc Gittelman

MD, F.A.C.S. - South Florida Medical Research - Director

- Board certified urologist who is an investigator and the central reader for the uroflow (Qmax) assessment in the topsalysin Phase 3 PLUS-1 BPH study
- Involved in the clinical trials of all approved oral medications for BPH as well as a trial of a minimally invasive surgical technique or MIST
- Investigator in the clinical trials to other intraprostatic injectables that were evaluated by Allergan and Nymox



Hashim Ahmed

FRCS(Urol), PhD, BM, BCh (Oxon), BA(Hons)- University College Hospital - MRC Clinician Scientist, Honorary Consultant Urological Surgeon

- Principal investigator for the topsalysin localized prostate cancer study at the Division of Surgery and Interventional Sciences at the University College London in the UK
- World-renowned expert in the focal treatment of localized disease
- Participated on FDA and other regulatory health authority panels advising on how best to move the field of focal treatment of localized prostate cancer forward
- Personally administered topsalysin to all of the 18 patients with localized prostate cancer that have been treated in the proof of concept study